Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/28896
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSteingo, Brian-
dc.contributor.authorOreja-Guevara, Celia-
dc.contributor.authorAlroughani, Raed-
dc.contributor.authorBrassat, David-
dc.contributor.authorBoyko, Alexey N.-
dc.contributor.authorMcCombe, Pamela-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorMargolin, David H.-
dc.contributor.authorMelanson, Maria-
dc.contributor.authorDaizadeh, Nadia-
dc.contributor.authorRodriguez, Claudio E.-
dc.contributor.authorVermersch, Patrick-
dc.date.accessioned2019-08-06T15:23:43Z-
dc.date.available2019-08-06T15:23:43Z-
dc.date.issued2018-
dc.identifier.citationNEUROLOGY, 90(15) (Art N° P6.376)-
dc.identifier.issn0028-3878-
dc.identifier.urihttp://hdl.handle.net/1942/28896-
dc.description.sponsorshipSanofi and Bayer HealthCare Pharmaceuticals.-
dc.language.isoen-
dc.publisherLIPPINCOTT WILLIAMS & WILKINS-
dc.rights2018, American Academy of Neurology-
dc.titleDurable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateAPR 21-27, 2018-
local.bibliographicCitation.conferencename70th Annual Meeting of the American-Academy-of-Neurology (AAN)-
local.bibliographicCitation.conferenceplaceLos Angeles, CA-
dc.identifier.volume90(15)-
local.format.pages3-
local.bibliographicCitation.jcatM-
dc.description.notes[Steingo, Brian] Ft Lauderdale Multiple Sclerosis Ctr, Ft Lauderdale, FL USA. [Oreja-Guevara, Celia] Univ Hosp San Carlos, Madrid, Spain. [Alroughani, Raed] Amiri Hosp, Sharq, Kuwait. [Brassat, David] Univ Toulouse, Purpan Hosp, Toulouse, France. [Brassat, David] Univ Toulouse, Mixed Unit Res 1043, Toulouse, France. [Boyko, Alexey N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, Alexey N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [McCombe, Pamela] Univ Queensland, Brisbane, Qld, Australia. [Van Wijmeersch, Bart] Hasselt Univ, Rehabil, Hasselt, Belgium. [Van Wijmeersch, Bart] Hasselt Univ, MS Ctr Overpelt, BIOMED, Hasselt, Belgium. [Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.] Sanofi, Cambridge, MA USA. [Vermersch, Patrick] Univ Lille, Lille, France.-
local.publisher.placePHILADELPHIA-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrP6.376-
dc.identifier.isi000453090805102-
item.fulltextWith Fulltext-
item.contributorSteingo, Brian-
item.contributorOreja-Guevara, Celia-
item.contributorAlroughani, Raed-
item.contributorBrassat, David-
item.contributorBoyko, Alexey N.-
item.contributorMcCombe, Pamela-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorMargolin, David H.-
item.contributorMelanson, Maria-
item.contributorDaizadeh, Nadia-
item.contributorRodriguez, Claudio E.-
item.contributorVermersch, Patrick-
item.accessRightsRestricted Access-
item.fullcitationSteingo, Brian; Oreja-Guevara, Celia; Alroughani, Raed; Brassat, David; Boyko, Alexey N.; McCombe, Pamela; VAN WIJMEERSCH, Bart; Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E. & Vermersch, Patrick (2018) Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study). In: NEUROLOGY, 90(15) (Art N° P6.376).-
crisitem.journal.issn0028-3878-
crisitem.journal.eissn1526-632X-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Schmidtea mediterranea as an alternative model to predict carcinogenicity via its stem cell responses _ Elsevier Enhanced Reader.pdf
  Restricted Access		Published version712.7 kBAdobe PDFView/Open    Request a copy
Show simple item record

Page view(s)

20
checked on Sep 7, 2022

Download(s)

6
checked on Sep 7, 2022

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.